Dennis Mulroy serves as the Chief Financial Officer (CFO) at ANAPTYSBIO INC, a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. With over two decades of experience in financial management and strategic planning within the biotechnology sector, Mulroy has been instrumental in guiding ANAPTYSBIO's financial operations and growth strategy. Prior to joining ANAPTYSBIO, he held significant roles at various biotech firms, including CFO positions at companies such as Halozyme Therapeutics and Amylin Pharmaceuticals, where he successfully managed complex financial landscapes and led multiple successful financings and strategic transactions. At ANAPTYSBIO, Mulroy is responsible for overseeing all aspects of the company's financial strategy, including budgeting, forecasting, and investor relations. His expertise in capital markets has been crucial in securing funding to support the company's research and development efforts. Under his leadership, ANAPTYSBIO has navigated through several key milestones, including advancing its pipeline of novel therapeutics and maintaining a strong financial position. Mulroy's strategic vision and financial acumen have been vital in positioning ANAPTYSBIO as a leader in the biotechnology industry, dedicated to bringing life-changing treatments to patients with serious medical conditions. In addition to his professional achievements, Mulroy is recognized for his contributions to the broader biotech community. He has been a speaker at various industry conferences and has shared his insights on financial strategies for growth-stage biotech companies. His commitment to excellence and innovation in financial management continues to drive ANAPTYSBIO's success and its mission to improve patient outcomes through cutting-edge science.